Spyre Therapeutics Inc. (SYRE) enrolls first patient in its Phase 2 SKYWAY trial targeting multiple autoimmune diseases. The study will assess the company’s lead antibody program in patients unresponsive to standard treatments. Initial data expected in 2026, with proof-of-concept readouts planned over the next two years. SYRE is a clinical-stage biotech developing therapies for inflammatory bowel disease.

Read more at Yahoo Finance: Spyre Therapeutics Inc. (SYRE) Enrolls First Patient in Its Patient 2 SKYWAY Trial